TORONTO, Sept. 13 /PRNewswire-FirstCall/ - Transition Therapeutics Inc. (Transition) (TSX: TTH - News), announced today that it has established a partnership with the Juvenile Diabetes Research Foundation (JDRF) to support a clinical development plan for Transition’s diabetes regenerative product, GLP1-I.N.T.(TM)
